DE602006005826D1 - Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom - Google Patents

Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom

Info

Publication number
DE602006005826D1
DE602006005826D1 DE602006005826T DE602006005826T DE602006005826D1 DE 602006005826 D1 DE602006005826 D1 DE 602006005826D1 DE 602006005826 T DE602006005826 T DE 602006005826T DE 602006005826 T DE602006005826 T DE 602006005826T DE 602006005826 D1 DE602006005826 D1 DE 602006005826D1
Authority
DE
Germany
Prior art keywords
delivery system
chronotherapeutic
treatment
prostagelines
betabole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006005826T
Other languages
English (en)
Inventor
Barbara R Conway
Doina Gherghel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aston University
Original Assignee
Aston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0519270A external-priority patent/GB0519270D0/en
Priority claimed from GB0608181A external-priority patent/GB0608181D0/en
Application filed by Aston University filed Critical Aston University
Publication of DE602006005826D1 publication Critical patent/DE602006005826D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602006005826T 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom Active DE602006005826D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0519270A GB0519270D0 (en) 2005-09-21 2005-09-21 Chronotherapeutic delivery system for treatment of glaucoma
GB0608181A GB0608181D0 (en) 2006-04-25 2006-04-25 Chronotherapeutic Delivery System For Treatment Of Glaucoma
PCT/GB2006/003366 WO2007034140A1 (en) 2005-09-21 2006-09-11 Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma

Publications (1)

Publication Number Publication Date
DE602006005826D1 true DE602006005826D1 (de) 2009-04-30

Family

ID=37605837

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006005826T Active DE602006005826D1 (de) 2005-09-21 2006-09-11 Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom

Country Status (6)

Country Link
US (1) US20090155338A1 (de)
EP (1) EP1928407B1 (de)
AT (1) ATE425740T1 (de)
DE (1) DE602006005826D1 (de)
ES (1) ES2326282T3 (de)
WO (1) WO2007034140A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010105130A2 (en) * 2009-03-13 2010-09-16 Vista Scientific Llc Opthalmic drug delivery system and applications
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102596097B (zh) 2009-06-03 2015-05-20 弗赛特实验室有限责任公司 一种眼插入件
US20130142858A1 (en) * 2010-05-17 2013-06-06 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
AU2012308317B2 (en) 2011-09-14 2017-01-05 Forsight Vision5, Inc. Ocular insert apparatus and methods
SI2911623T1 (sl) 2012-10-26 2019-12-31 Forsight Vision5, Inc. Oftalmični sistem za podaljšano sproščanje zdravila v oko
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
AU2015266850B2 (en) * 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
AU2017252294B2 (en) 2016-04-20 2021-12-02 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11672697B2 (en) 2018-06-19 2023-06-13 Twenty Twenty Therapeutics Llc Eye-mountable therapeutic devices, and associated systems and methods
US11395797B2 (en) * 2019-12-10 2022-07-26 Alcon Inc. Dissolvable polymeric eye inserts with a biodegradable polymer and method of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
CA2491313C (en) * 2002-07-15 2011-05-24 Alcon, Inc. Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
US6933289B2 (en) * 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods

Also Published As

Publication number Publication date
WO2007034140A1 (en) 2007-03-29
US20090155338A1 (en) 2009-06-18
EP1928407A1 (de) 2008-06-11
EP1928407B1 (de) 2009-03-18
ES2326282T3 (es) 2009-10-06
ATE425740T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
DE602006005826D1 (de) Chronotherapeutisches okulares abgabesystem aus einer kombination von prostaglandinen und einem betablocker zur behandlung von primärem glaukom
EP4282486A3 (de) Komplementfaktor-b-inhibitor und pharmazeutische zusammensetzung davon, herstellungsverfahren dafür und verwendung davon
MX2021012862A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
DE102005053680A1 (de) Synergistische insektizide Mischungen zur Behandlung von Saatgut
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE502005001828D1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
ATE446744T1 (de) Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit
EP2301355A3 (de) Insektizide auf Basis von Neonicotinoiden und ausgewählten Strobilurinen
UA100526C2 (ru) Способ и композиция для обработки семян
ATE533493T1 (de) Schäumende pharmazeutische zusammensetzungen und verfahren zur behandlung einer erkrankung
JP2003505422A5 (de)
EP2177224A3 (de) Mittel zur Vorbeugung und Behandlung von Erkrankungen mit RyR-Rezeptormodulation
ATE455534T1 (de) Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
PT1778680E (pt) Derivados espirocíclicos de ciclo-hexano
UA86441C2 (ru) (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
CR20120151A (es) Combinaciones de compuestos activos
BRPI0801239A2 (pt) uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
EA201790382A1 (ru) Способы лечения периимплантита
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
EP3845516A4 (de) Neuer hif-1alfa-inhibitor, verfahren zu seiner herstellung und pharmazeutische zusammensetzung zur vorbeugung oder behandlung einer angiogenese-assoziierten augenerkrankung, die diesen als wirkstoff enthält
BR102020008189A8 (pt) Uso de uma quantidade eficaz de 2-(1,5-dimetil-3-fenil-1hpirrol-2-il)-n- (4-(4-(5-fluoropirimidin-2-il)piperazin-1-il)fenil)-2- oxoacetamida, ou um sal farmaceuticamente aceitável do mesmo
MX2009004792A (es) Moduladores de la union de pai-1 para el tratamiento de trastornos oculares.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition